CEACAM5 and neoplasm: The SECA-1 trial reported that factors associated with decreased survival included pretransplant maximal tumor diameter exceeding 5.5 cm, level of carcinoembryonic antigen (CEA) before LT > 80 mg/L, failing response on chemotherapy, and short interval from resection of the primary to LT.